Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 6/20 | 0.57 |
| ▸ | AKR1C2 | P52895 | 6/20 | 0.57 |
| ▸ | AKR1C1 | Q04828 | 4/20 | 0.57 |
| ▸ | APP | P05067 | 8/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 5/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 5/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.54 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.51 |
| ▸ | AKR1C4 | P17516 | 1/20 | 0.51 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.51 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.51 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.51 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.51 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.51 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.51 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2794618 | 0.96 | AKR1C3 (0.57) | AKR1C3AKR1C2AKR1C1APPCYP2C19 | |
| SCHEMBL1465878 | 0.93 | AKR1C3 (0.65) | AKR1C3AKR1C2AKR1C1APPCYP2C19 | |
| SCHEMBL1626823 | 0.85 | AKR1C3 (0.54) | AKR1C3AKR1C2AKR1C1APPCYP2C19 | |
| SCHEMBL18742537 | 0.84 | LMNA (0.53) | AKR1C3AKR1C2AKR1C1APPCYP2C19 | |
| SCHEMBL12020377 | 0.83 | HDAC4 (0.43) | AKR1C3AKR1C2AKR1C1APPCYP2C19 | |
| SCHEMBL17713205 | 0.83 | APP (0.55) | AKR1C3AKR1C2AKR1C1APPCYP2C19 | |
| SCHEMBL5723716 | 0.81 | AKR1C3 (0.70) | AKR1C3AKR1C2AKR1C1APPCYP2C19 | |
| SCHEMBL1371930 | 0.81 | APP (0.82) | AKR1C3AKR1C2AKR1C1APPCYP2C19 | |
| SCHEMBL8484905 | 0.81 | APP (0.47) | AKR1C3AKR1C2AKR1C1APPCYP2C19 | |
| SCHEMBL13253747 | 0.80 | AKR1C3 (0.56) | AKR1C3AKR1C2AKR1C1APPCYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109219602-A | Modulators of cystic fibrosis transmembrane conductance regulator proteins | 艾伯维公司 | 2019-01-15 | — | — | CN | disclosed |
| US-10118916-B2 | Modulators of cystic fibrosis transmembrane conductance regulator protein | ABBVIE S.Á.R.L. (LU) | 2018-11-06 | — | — | US | disclosed |
| WO-2017187321-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR PROTEIN | AbbVie S.à.r.l. (LU) | 2017-11-02 | — | — | WO | disclosed |
| US-20170305891-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR PROTEIN | ABBVIE S.Á.R.L. (LU) | 2017-10-26 | — | — | US | disclosed |
| EP-1532122-B1 | 11-beta-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipidemia | MERCK SHARP & DOHME (US) | 2011-12-14 | — | — | EP | disclosed |
| EP-1532122-B1 | 11-beta-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipidemia | MERCK SHARP & DOHME (US) | 2011-12-14 | — | — | EP | disclosed |
| US-20100168102-A9 | Amide Derivatives as Kinase Inhibitors | DEVGEN NV (BE) | 2010-07-01 | — | — | US | disclosed |
| US-20100168102-A9 | Amide Derivatives as Kinase Inhibitors | DEVGEN NV (BE) | 2010-07-01 | — | — | US | disclosed |
| US-20100168102-A9 | Amide Derivatives as Kinase Inhibitors | DEVGEN NV (BE) | 2010-07-01 | — | — | US | disclosed |
| US-20090118283-A1 | Amide Derivatives as Kinase Inhibitors | DEVGEN NV (BE) | 2009-05-07 | — | — | US | disclosed |
| US-20090118283-A1 | Amide Derivatives as Kinase Inhibitors | DEVGEN NV (BE) | 2009-05-07 | — | — | US | disclosed |
| US-7179802-B2 | 11-beta-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipidemia | MERCK & CO., INC. (US) | 2007-02-20 | — | — | US | disclosed |
| US-7179802-B2 | 11-beta-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipidemia | MERCK & CO., INC. (US) | 2007-02-20 | — | — | US | disclosed |
| US-7179802-B2 | 11-beta-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipidemia | MERCK & CO., INC. (US) | 2007-02-20 | — | — | US | disclosed |
| EP-1532122-A1 | 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 INHIBITORS USEFUL FOR THE TREATMENT OF DIABETES, OBESITY AND DYSLIPIDEMIA | Merck & Co., Inc. (US) | 2005-05-25 | — | — | EP | disclosed |
| US-20040106664-A1 | 11-Beta-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipidemia | MERCK SHARP & DOHME LLC | 2004-06-03 | — | — | US | disclosed |
| US-6730690-B2 | DELAYING THE ONSET OR REDUCING THE RISK OF DEVELOPING ATHEROSCLEROSIS IN A HUMAN PATIENT COMPRISING ADMINISTERING TO SAID PATIENT AN EFFECTIVE AMOUNT OF A COMPOUND OF INVENTION AND AN HMG-COA REDUCTASE INHIBITOR | MERCK & CO., INC. | 2004-05-04 | — | — | US | disclosed |
| US-20040048912-A1 | 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 INHIBITORS USEFUL FOR THE TREATMENT OF DIABETES, OBESITY AND DYSLIPIDEMIA | MERCK SHARP & DOHME LLC | 2004-03-11 | — | — | US | disclosed |
| WO-2003104208-A1 | 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 INHIBITORS USEFUL FOR THE TREATMENT OF DIABETES, OBESITY AND DYSLIPIDEMIA | MERCK & CO., INC. (US) | 2003-12-18 | — | — | WO | disclosed |
| WO-2003104207-A2 | 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 INHIBITORS USEFUL FOR THE TREATMENT OF DIABETES, OBESITY AND DYSLIPIDEMIA | MERCK & CO., INC. (US) | 2003-12-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040048912-A1 | 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 INHIBITORS USEFUL FOR THE TREATMENT OF DIABETES, OBESITY AND DYSLIPIDEMIA | HSD11B1, HSD17B1, HSD11B2 | AKR1C3 203/4885AKR1C2 98/4885AKR1C1 86/4885 |
| US-20040106664-A1 | 11-Beta-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipidemia | HSD11B1, HSD11B2, HSD17B1 | AKR1C3 201/4885AKR1C2 87/4885AKR1C1 95/4885 |
| US-20100168102-A9 | Amide Derivatives as Kinase Inhibitors | MAP3K1, CDK1, CDK2 | AKR1C3 493/4885AKR1C2 405/4885AKR1C1 362/4885 |
| US-20170305891-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR PROTEIN | CFTR, CHRM2, CHRM1 | AKR1C3 1461/4885AKR1C2 2755/4885AKR1C1 2204/4885 |
| US-20090118283-A1 | Amide Derivatives as Kinase Inhibitors | MAP3K1, CDK1, CDK2 | AKR1C3 493/4885AKR1C2 405/4885AKR1C1 362/4885 |
| US-10118916-B2 | Modulators of cystic fibrosis transmembrane conductance regulator protein | CFTR, CHRM2, CHRM1 | AKR1C3 1461/4885AKR1C2 2755/4885AKR1C1 2204/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.